# US 2014/0371243 A1 · Medical use of a dpp-4 inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0371243 A1
- Document ID: US20140371243A1
- Status: Published application
- Kind: A1
- Application number: 14/303,852
- Filed: 2014-06-13
- Published: 2014-12-18
- Earliest claimed: 2013-06-14
- Assignees: Boehringer Ingelheim International GmbH
- Inventors: Thomas KLEIN; Takashi NOMIYAMA; Yuichi TERAWAKI; Toshihiko YANASE
- Web page: https://patentgrep.com/patent/US20140371243A1

## CPC

- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of a certain DPP-4 inhibitor along with angioplasty or stenting, and/or to its use for treating and/or preventing restenosis from angioplasty or stenting.

## Claims

### Claim 1

A method of treating a patient who is in need of, indicated for or has undergone angioplasty and/or stenting, the method comprising administering a DPP-4 inhibitor, optionally in combination with one or more other active agents, to the patient.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the DPP-4 inhibitor is used along with angioplasty and/or stenting.

### Claim 3 (depends on 1)

The method according to claim 1 for treating, preventing and/or reducing the risk of complications associated with or following angioplasty and/or stenting.

### Claim 4 (depends on 1)

The method according to claim 1 for treating, preventing and/or reducing the risk of restenosis from or in angioplasty or stenting.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the angioplasty is peripheral or coronary angioplasty.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the angioplasty is performed as stent implantation, bypass operation or balloon cathetering.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the angioplasty is performed as stent implantation.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the DPP-4 inhibitor is used in combination with angioplasty or stenting.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the DPP-4 inhibitor is used in combination with a stent.

### Claim 10 (depends on 1)

The method according to claim 1, wherein DPP-4 inhibitor is administered orally, optionally in combination with angioplasty or stenting.

### Claim 11 (depends on 1)

The method according to claim 1, wherein DPP-4 inhibitor is applied together with a implantable stent.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the patient is a diabetic patient.

### Claim 13 (depends on 1)

The method according to claim 1, further for treating diabetes.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the patient is a non-diabetic patient.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the DPP-IV inhibitor is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine.

### Claim 16 (depends on 3)

The method according to claim 3, wherein the one or more complications is selected from the group consisting of selected from restenosis, blood clots, neointimal hyperplasia and major adverse cardiac events (MACE).

### Claim 17 (depends on 16)

The method according to claim 16, wherein restenosis is in-stent restenosis (ISR) or post-angioplasty restenosis (PARS).

### Claim 18 (depends on 8)

The method according to claim 8, wherein the DPP-4 inhibitor is used simultaneously, concurrently, separately, sequentially or subsequently with angioplasty or stenting.

### Claim 19 (depends on 8)

The method according to claim 8, wherein the DPP-4 inhibitor is used in fixed or free combination with a stent.

### Claim 20 (depends on 11)

The method according to claim 11, wherein the stent is a drug-eluting stent for release of the DPP-4 inhibitor.
